Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial

Gazzard G.; Konstantakopoulou E.; Garway-Heath D.; Garg Anurag; Vickerstaff V.; Hunter Rachael; Ambler Gareth; Bunce Catey; Wormald Richard; Nathwani N.; Barton Keith; Rubin Gary S.; Buszewicz Marta; Davi Gareth Keith Rupert David Catey Marta Amanda Anurag David Ambler Barton Bourne Broadway Bunce Buszewicz; Ambler Gareth; Barton Keith; Bourne R.; Broadway D.; Bunce Catey; Buszewicz Marta; Davis A.; Garg Anurag; Garway-Heath D.; Gazzard G.; Hunter Rachael; Jayaram H.; Jiang Yuzhen; Konstantakopoulou E.; Lim Sheng; Liput J.; Manners T.; Morris Stephen; Nathwani N.; Rubin Gary S.; Strouthidis N.; Vickerstaff V.; Wilson S.; Wormald Richard; Zhu Haogang

doi:10.1016/s0140-6736(18)32213-x

← Today's brief

L2 StudySurrogate endpoint

Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial

Gazzard G. et al. · Lancet (London, England) · Tuesday, January 1, 2019

Read original

Design Level 2n 718Funding Not reported

The one catch: Surrogate endpoint, not a direct patient outcome.

Source

Gazzard G. et al.. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial Lancet (London, England). Tuesday, January 1, 2019.
doi:10.1016/s0140-6736(18)32213-x

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.